Arrowhead Pharmaceuticals Inc. (ARWR)

18.85
0.02 0.11
NASDAQ : Health Technology
Prev Close 18.83
Open 18.79
Day Low/High 18.27 / 19.00
52 Wk Low/High 6.12 / 22.39
Volume 512.48K
Avg Volume 1.78M
Exchange NASDAQ
Shares Outstanding 94.21M
Market Cap 1.78B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1)

Arrowhead Announces Patent Issuance Covering SiRNA Inhibitors Of HIF-2α (EPAS1)

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that the United States Patent and Trademark Office (USPTO) has issued U.

Arrowhead Reports Fiscal 2012 First Quarter Financial Results

Arrowhead Reports Fiscal 2012 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended December 31, 2011.

Arrowhead To Report Fiscal 2012 First Quarter Financial Results

Arrowhead To Report Fiscal 2012 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 first quarter ended December 31, 2011, on Thursday, February 9, 2012 at 4:30 p.

Alnylam And Arrowhead Form Collaboration And Licensing Agreement

Alnylam And Arrowhead Form Collaboration And Licensing Agreement

Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Arrowhead Research Corporation, (Nasdaq: ARWR) a nanomedicine company with development programs in RNAi and obesity,...

Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial

Arrowhead Announces FDA Clearance To Initiate AdipotideTM Phase I Clinical Trial

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug...

Arrowhead Reports Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2011 fourth quarter and year ended September 30,...

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. To Board Of Directors

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. To Board Of Directors

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S.

Arrowhead To Report Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead To Report Fiscal 2011 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2011 fourth quarter and year ended September 30, 2011, on Tuesday, December 20, 2011 at 4:30 p.

Arrowhead Research Appoints Drs. David Lewis And David Rozema To Lead Operations At Madison, WI Facility

Arrowhead Research Appoints Drs. David Lewis And David Rozema To Lead Operations At Madison, WI Facility

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed David Lewis, Ph.

Arrowhead Research Announces 1-for-10 Reverse Stock Split

Arrowhead Research Announces 1-for-10 Reverse Stock Split

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the implementation of a 1-for-10 reverse stock split of...

Leonardo Biosystems Receives Second $1.25 Million Investment From The Texas Emerging Technology Fund

Leonardo Biosystems Receives Second $1.25 Million Investment From The Texas Emerging Technology Fund

Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.

6 Stocks Hitting New 52-Week Highs

6 Stocks Hitting New 52-Week Highs

When a stock hits a new 52-week high, it often indicates a very strong uptrend.

Arrowhead Research Subsidiary Ablaris Therapeutics Data Published In Science Translational Medicine Demonstrates Weight Loss In Obese Monkeys

Arrowhead Research Subsidiary Ablaris Therapeutics Data Published In Science Translational Medicine Demonstrates Weight Loss In Obese Monkeys

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of data from Ablaris Therapeutics, Inc.

Arrowhead Research Publishes White Paper On RNAi Delivery Technology Acquired From Roche

Arrowhead Research Publishes White Paper On RNAi Delivery Technology Acquired From Roche

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview...

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed Brendan P.

Vascular Research Further Validates The Drug Development Programs Of Arrowhead Research Subsidiary Ablaris Therapeutics And Alvos Therapeutics

Vascular Research Further Validates The Drug Development Programs Of Arrowhead Research Subsidiary Ablaris Therapeutics And Alvos Therapeutics

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that a paper further validating the drug development programs of Ablaris Therapeutics, Inc.

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.

Arrowhead Research Corporation Acquires Roche RNA Assets And Site

Arrowhead Research Corporation Acquires Roche RNA Assets And Site

Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has acquired RNA therapeutics assets from Roche (SIX: RO, ROG; OTCQX: RHHBY) including the state-of-the-art research site in Madison, WI.

Arrowhead Research Corporation Completes $5.5 Million Private Placement

Arrowhead Research Corporation Completes $5.5 Million Private Placement

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that on September 30, 2011, it closed a private placement of approximately 14.

Arrowhead Reports Fiscal 2011 Third Quarter Financial Results

Arrowhead Reports Fiscal 2011 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 third quarter...

Arrowhead Research To Report Fiscal 2011 Third Quarter Financial Results And Host Conference Call On Monday, August 8, 2011

Arrowhead Research To Report Fiscal 2011 Third Quarter Financial Results And Host Conference Call On Monday, August 8, 2011

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2011 third quarter ended June 30, 2011, on Monday, August 8, 2011 at 4:30 p.

Arrowhead Research Announces Oncology Expert Timothy J. Triche To Join Calando Scientific Advisory Board

Arrowhead Research Announces Oncology Expert Timothy J. Triche To Join Calando Scientific Advisory Board

Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that Timothy J.

Arrowhead Research To Present At Two Nanomedicine-Focused Events In London

Arrowhead Research To Present At Two Nanomedicine-Focused Events In London

Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief Executive Officer ...

Arrowhead Research President & CEO Christopher Anzalone Featured In The Wall Street Transcript Interview

Arrowhead Research President & CEO Christopher Anzalone Featured In The Wall Street Transcript Interview

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and CEO Christopher Anzalone, Ph.

Arrowhead Receives Additional 180 Day Grace Period To Comply With The NASDAQ $1.00 Minimum Bid Requirement

Arrowhead Receives Additional 180 Day Grace Period To Comply With The NASDAQ $1.00 Minimum Bid Requirement

In first graph, first sentence of release, date should read: June 7, 2011 (sted June 7, 2017).

Arrowhead Reports Fiscal 2011 Second Quarter Financial Results

Arrowhead Reports Fiscal 2011 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 second quarter...

Arrowhead Research To Report Fiscal 2011 Second Quarter Financial Results And Host Conference Call On Thursday, May 12, 2011

Arrowhead Research To Report Fiscal 2011 Second Quarter Financial Results And Host Conference Call On Thursday, May 12, 2011

Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that it will report its financial results for the fiscal...

Arrowhead Research To Present At The 2011 MDB Capital Group Bright Lights Conference On May 10

Arrowhead Research To Present At The 2011 MDB Capital Group Bright Lights Conference On May 10

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr.

Arrowhead Research Announces RNAi Leader John J. Rossi, Ph.D. To Join Calando Scientific Advisory Board

Arrowhead Research Announces RNAi Leader John J. Rossi, Ph.D. To Join Calando Scientific Advisory Board

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that John J.

TheStreet Quant Rating: D (Sell)